In the Headlines
November 6, 2026

Democrats' Victory Tees Up Focus on Trump's Big Pharma Deals

Bloomberg Law

Healthcare Senior Policy Advisor Miranda Franco was mentioned in a Bloomberg Law article previewing congressional scrutiny of President Donald Trump's drug pricing agreements with major pharmaceutical companies. Under the administration's Most-Favored-Nation (MFN) policy, companies agreed to adjust drug prices in the U.S. to align with better prices in peer countries in exchange for tariff relief and an exemption from Medicare mandatory price cuts. Democratic lawmakers, set to take control of Congress in January, have stated their intention to investigate these agreements to determine whether they meaningfully lower healthcare costs for patients and the government, pledging to utilize subpoenas and other oversight powers to dig more deeply into the deals. Miranda mentioned that simultaneously, Democrats can use their new majority power to focus on other ways of lowering medical costs, such as expanding the list of drugs for Medicare price negotiations or selecting products earlier for the program. The leverage also gives the party a chance to tout drug price-related provisions in the Inflation Reduction Act, she added.

READ: Democrats' Victory Tees Up Focus on Trump's Big Pharma Deals (Subscription required)

Related News and Headlines